Evolus (NASDAQ:EOLS) Trading Down 9.6% – What’s Next?

Evolus, Inc. (NASDAQ:EOLS) shares were down 9.6% during trading on Monday . The company traded as low as $12.56 and last traded at $12.28. Approximately 206,913 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 592,049 shares. The stock had previously closed at $13.58.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Wednesday, March 5th. Finally, Barclays boosted their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th.

Evolus Stock Down 11.8 %

The company has a market capitalization of $761.71 million, a P/E ratio of -13.16 and a beta of 1.28. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company has a 50 day moving average of $12.95 and a 200-day moving average of $14.05.

Institutional Investors Weigh In On Evolus

Several hedge funds have recently bought and sold shares of EOLS. KBC Group NV purchased a new stake in shares of Evolus in the fourth quarter worth $49,000. IFP Advisors Inc raised its holdings in Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after buying an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Evolus in the fourth quarter worth approximately $106,000. Rafferty Asset Management LLC purchased a new stake in shares of Evolus during the fourth quarter valued at approximately $115,000. Finally, Quantbot Technologies LP bought a new stake in shares of Evolus during the fourth quarter valued at approximately $118,000. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.